Bausch Health (BHC)
(Real Time Quote from BATS)
$7.14 USD
+0.02 (0.28%)
Updated May 15, 2024 10:44 AM ET
3-Hold of 5 3
A Value C Growth F Momentum B VGM
Brokerage Reports
Bausch Health Cos Inc. [BHC]
Reports for Purchase
Showing records 121 - 140 ( 148 total )
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Progress on Multiple Fronts; 2019 Guidance Implies Gradual Growth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Headwinds Abating; Debt Seems Manageable; Synergy Bid Intrigues; Upgrading to Buy and $58 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
ALTRENO Lotion Pivotal Data Published; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
BRYHALI Lotion Receives Tentative FDA Approval; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R